Endpoints: Escaping an improbable upbringing, Greg Verdine places his biggest career bets in drugging the ‘undruggable’ Read More
Insider: A former Harvard chemist just raised $178 million for a biotech startup that plans to treat previously untreatable cancers Read More
Endpoints: Harvard’s Gregory Verdine has big ambitions for his miniprotein ‘braces’ — and now $107M to guide them to the clinic Read More
Cambridge Discovery Park Building 400-500 Will be New Headquarters for FogPharma and LifeMine Therapeutics Read More
Endpoints: His way: Greg Verdine is building a new kind of drug, with backing from a different kind of investor Read More